Stock Events

Stock Events

Terns Pharmaceuticals 

€44.74
43
+€0.1+0.22% Thursday 06:03

Statistics

Day High
44.74
Day Low
44.74
52W High
46.2
52W Low
2.5
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q4 2025
Next
-0.25
-0.24
-0.23
-0.21
Expected EPS
-0.21477010112999997
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 430.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a leading biopharmaceutical company that competes with Terns Pharmaceuticals in the development of treatments for liver diseases, including NASH, which is a focus area for Terns.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.84B
Madrigal Pharmaceuticals focuses on the development of therapies for cardiovascular, metabolic, and liver diseases, including NASH, directly competing with Terns Pharmaceuticals' interests.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is involved in developing treatments for metabolic and endocrine disorders, including NASH, positioning it as a competitor to Terns Pharmaceuticals.
Galmed Pharmaceuticals
GLMD
Mkt Cap3.77M
Galmed Pharmaceuticals competes in the NASH treatment space, making it a direct competitor to Terns Pharmaceuticals with its focus on liver diseases.
Agios Pharmaceuticals
AGIO
Mkt Cap1.67B
Agios Pharmaceuticals, while focusing on cellular metabolism to treat diseases, has interests in liver diseases, indirectly competing with Terns Pharmaceuticals.
Enanta Pharmaceuticals
ENTA
Mkt Cap421.94M
Enanta Pharmaceuticals is focused on liver diseases and respiratory infections, making it a competitor in the liver disease space, including NASH, where Terns is active.

About

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Show more...
CEO
Ms. Amy L. Burroughs M.B.A.
Employees
59
Country
United States
ISIN
US8808811074

Listings

STU
DE
430.STU
MU
DE
430.MU
XNAS
US
TERN
F
DE
430.F

0 Comments

Share your thoughts

FAQ

What is Terns Pharmaceuticals stock price today?▼
The current price of 430.MU is €44.74 EUR — it has increased by +0.22% in the past 24 hours. Watch Terns Pharmaceuticals stock price performance more closely on the chart.
What is Terns Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Terns Pharmaceuticals stocks are traded under the ticker 430.MU.
Is Terns Pharmaceuticals stock price growing?▼
430.MU stock has risen by +0.22% compared to the previous week, the month change is a -1.89% fall, over the last year Terns Pharmaceuticals has showed a +1,432.19% increase.
When is the next Terns Pharmaceuticals earnings date?▼
Terns Pharmaceuticals is going to release the next earnings report on May 18, 2026.
What were Terns Pharmaceuticals earnings last quarter?▼
430.MU earnings for the last quarter are -0.24 EUR per share, whereas the estimation was -0.25 EUR resulting in a +6.18% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Terns Pharmaceuticals have?▼
As of May 06, 2026, the company has 59 employees.
In which sector is Terns Pharmaceuticals located?▼
Terns Pharmaceuticals operates in the Health & Wellness sector.
When did Terns Pharmaceuticals complete a stock split?▼
Terns Pharmaceuticals has not had any recent stock splits.
Where is Terns Pharmaceuticals headquartered?▼
Terns Pharmaceuticals is headquartered in Foster City, United States.